[go: up one dir, main page]

AR073116A1 - Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes. - Google Patents

Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes.

Info

Publication number
AR073116A1
AR073116A1 ARP090103233A ARP090103233A AR073116A1 AR 073116 A1 AR073116 A1 AR 073116A1 AR P090103233 A ARP090103233 A AR P090103233A AR P090103233 A ARP090103233 A AR P090103233A AR 073116 A1 AR073116 A1 AR 073116A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
group
substituted
membered
Prior art date
Application number
ARP090103233A
Other languages
English (en)
Original Assignee
Novartis Ag
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Astex Therapeutics Ltd filed Critical Novartis Ag
Publication of AR073116A1 publication Critical patent/AR073116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable, en donde: X es CR9 o N; R1 es alquilo C1-8, CN, C(O)OR4 o CONR5R6, un grupo heteroarilo de 5 a 14 miembros, o un grupo ciclo heteroalquilo de 3 a 14 miembros; R2 es alquilo C1-8, cicloalquilo C3-14, o un grupo heteroarilo de 5 a 14 miembros, y en donde R2 puede estar sustituido con uno o más de alquilo C1-8, u OH; L es un enlace, alquileno C1-8, C(O), o C(O)NR10, y en donde L puede estar sustituido o insustituido; Y es H, R11, NR12R13, OH, o Y es parte del grupo de la formula (2) en donde Y es CR9 o N; en donde puede haber de 0 a 3 R8 presentes, y R8 es alquilo C1-8, oxo, halogeno, o dos o más R8 pueden formar un grupo alquilo puenteado; W es CR9 o N; R3 es H, alquilo C1-8, alquilo C1-8-R14, cicloalquilo C3-14, C(O)-alquilo C1-8, halo-alquilo C1-8, alquilo C1-8-OH, C(O)NR14R15, ciano-alquilo C1-8, C(O)R14, alquilo C0-8-C(O)-alquilo C0-8-NR14R15, alquilo C0-8-C(O)OR14, NR14R15, SO2-alquilo C1-8, alquilo C1-8-cicloalquilo C3-14, C(O)-alquilo C1-8-cicloalquilo C3-14, alcoxilo C1-8, u OH, el cual puede estar sustituido o insustituido cuando R3 no es H; R9 es H o halogeno; R4, R5, R6, R7, R10, R11, R12, R13, R14 y R15 se seleccionan cada uno independientemente a partir de H, alquilo C1-8, cicloalquilo C3-14, un grupo ciclo-heteroalquilo de 3 a 14 miembros, un grupo arilo C6-14, un grupo heteroarilo de 5 a 14 miembros, alcoxilo, C(O)H, C(N)OH, C(N)OCH3, C(O)-alquilo C1-3, alquilo C1-8-NH2, alquilo C1-6-OH, y en donde R4, R5, R6, R7, R10, R11, R12, R13, R14, y R15 cuando no son H, pueden estar sustituidos o insustituidos; m y n son independientemente de 0 a 2; y en donde L, R3, R4, R5, R6, R7, R10, R11, R12 y R13, R14 y R15 pueden estar sustituidos con uno o más de alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-14, grupo heteroarilo de 5 a 14 miembros, grupo arilo C6-14, un grupo ciclo-heteroalquilo de 3 a 14 miembros, OH, (O), CN, alcoxilo, halogeno o NH2. Reivindicacion 21: Un compuesto de la formula (3) o una sal farmacéuticamente aceptable del mismo, en donde: R50 es CONR54R55 o CN; R51 es cicloalquilo C3-14 el cual puede estar insustituido o sustituido por alquilo C1-3, u OH; Z es CH o N; y V es NR56 o CHR57; R54 y R55 son independientemente H, o alquilo C1-3; R52, R53, R56 y R57 son independientemente H, alquilo C1-8, cicloalquilo C3-14, halo-alquilo C1-8, NR58R59, C(O)OR60, C(O)-alquilo C1-8, alquilo C0-8-(O)-alquilo C0-8-NR61R62, alcoxilo C1-8, alquilo C1-8-R63, C(O)-grupo ciclo-heteroalquilo de 5 a 14 miembros, grupo cicloalquilo C3-14, cada uno de los cuales, cuando no es H, puede estar sustituido por uno o más de alquilo C1-8, OH o CN; R58, R59, R60, R61, R62 y R63 son H o alquilo C1-8.
ARP090103233A 2008-08-22 2009-08-21 Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes. AR073116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9103708P 2008-08-22 2008-08-22

Publications (1)

Publication Number Publication Date
AR073116A1 true AR073116A1 (es) 2010-10-13

Family

ID=41171100

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103233A AR073116A1 (es) 2008-08-22 2009-08-21 Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes.
ARP180101294A AR111763A2 (es) 2008-08-22 2018-05-16 Compuestos de pirrolo-pirimidina y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180101294A AR111763A2 (es) 2008-08-22 2018-05-16 Compuestos de pirrolo-pirimidina y sus usos

Country Status (48)

Country Link
US (8) US8685980B2 (es)
EP (2) EP2716643A1 (es)
JP (2) JP5560496B2 (es)
KR (2) KR20130140222A (es)
CN (2) CN102186856B (es)
AR (2) AR073116A1 (es)
AU (1) AU2009284098B2 (es)
BR (1) BRPI0917791B1 (es)
CA (1) CA2734802C (es)
CL (1) CL2011000306A1 (es)
CO (1) CO6341561A2 (es)
CR (1) CR20110101A (es)
CU (1) CU24062B1 (es)
CY (2) CY1115703T1 (es)
DK (1) DK2331547T3 (es)
DO (1) DOP2011000057A (es)
EA (1) EA019094B1 (es)
EC (1) ECSP11010843A (es)
ES (1) ES2522346T3 (es)
FR (1) FR17C1059I2 (es)
GE (1) GEP20135785B (es)
HN (1) HN2011000542A (es)
HR (1) HRP20141018T1 (es)
HU (1) HUS1700051I1 (es)
IL (1) IL211164A (es)
JO (1) JO2924B1 (es)
LT (1) LTC2331547I2 (es)
LU (1) LUC00048I2 (es)
MA (1) MA32555B1 (es)
ME (1) ME01282B (es)
MX (1) MX2011001879A (es)
MY (1) MY150560A (es)
NI (1) NI201100042A (es)
NL (1) NL300909I2 (es)
NO (1) NO2017059I1 (es)
NZ (1) NZ591176A (es)
PE (1) PE20110419A1 (es)
PL (1) PL2331547T3 (es)
PT (1) PT2331547E (es)
RS (1) RS53574B1 (es)
SI (1) SI2331547T1 (es)
SM (1) SMT201500017B (es)
TN (1) TN2011000062A1 (es)
TW (1) TWI468409B (es)
UA (1) UA103628C2 (es)
UY (2) UY32067A (es)
WO (1) WO2010020675A1 (es)
ZA (1) ZA201100994B (es)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
AU2010248886A1 (en) 2009-05-13 2011-12-01 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CN102869358B (zh) * 2010-04-13 2016-03-23 诺华股份有限公司 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
WO2012024500A1 (en) 2010-08-18 2012-02-23 Life Technologies Corporation Chemical coating of microwell for electrochemical detection device
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
HUE030714T2 (en) * 2010-10-25 2017-05-29 G1 Therapeutics Inc Cdk inhibitors
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
AU2011329763A1 (en) 2010-11-17 2013-05-09 Brigham And Women's Hospital Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
AU2014259534B2 (en) * 2011-01-04 2016-05-19 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
BR112013017316A2 (pt) * 2011-01-04 2019-09-24 Novartis Ag compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
EA030465B1 (ru) 2011-07-01 2018-08-31 Новартис Аг Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
WO2013006368A1 (en) 2011-07-01 2013-01-10 Novartis Ag Combination therapy
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US9194840B2 (en) 2012-01-19 2015-11-24 Life Technologies Corporation Sensor arrays and methods for making same
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
MY175254A (en) 2012-04-26 2020-06-17 G1 Therapeutics Inc Synthesis of lactams
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
HK1213044A1 (zh) 2012-08-03 2016-06-24 Foundation Medicine, Inc. 人乳头瘤病毒作为肿瘤预後的预测因子
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
ES2676177T3 (es) 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10011874B2 (en) 2013-02-25 2018-07-03 Novartis Ag Androgen receptor mutation
CA2901929A1 (en) * 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
CN105189481A (zh) 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
AU2014244194A1 (en) * 2013-03-14 2015-09-10 Abbvie Inc. Pyrrolopyrimindine CDK9 kinase inhibitors
JP2016516713A (ja) 2013-03-14 2016-06-09 アッヴィ・インコーポレイテッド ピロロ［２，３−ｂ］ピリジンｃｄｋ９キナーゼ阻害剤
US9073922B2 (en) 2013-03-14 2015-07-07 Abbvie, Inc. Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
SI2968290T1 (sl) 2013-03-15 2020-02-28 G1 Therapeutics, Inc., Prehodna zaščita normalnih celic med kemoterapijo
EP2967050A4 (en) * 2013-03-15 2016-09-28 G1 Therapeutics Inc HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
WO2014144596A2 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
JP6449234B2 (ja) 2013-03-21 2019-01-09 ノバルティス アーゲー 併用療法
WO2014172479A1 (en) 2013-04-16 2014-10-23 Memorial Sloan-Kettering Cancer Center Companion diagnostic for cdk4 inhibitors
DK3033086T3 (da) 2013-08-14 2022-01-03 Novartis Ag Kombinationsterapi til behandling af cancer
US20160361314A1 (en) * 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
TW201605857A (zh) * 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
US20160257688A1 (en) * 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
US20160375024A1 (en) * 2013-11-27 2016-12-29 Novartis Ag Combination therapy comprising an inhibitor of jak, cdk, and pim
US9476853B2 (en) 2013-12-10 2016-10-25 Life Technologies Corporation System and method for forming microwells
AU2014368927B2 (en) * 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
BR112016012506A8 (pt) * 2013-12-23 2018-01-30 Novartis Ag combinações farmacêuticas, seus usos, e uso de um portador de dados
ES2864352T3 (es) * 2013-12-23 2021-10-13 Novartis Ag Combinaciones farmacéuticas
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
JP6263269B2 (ja) * 2013-12-31 2018-01-17 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
CN106795179B (zh) * 2014-05-28 2019-09-17 锦州奥鸿药业有限责任公司 一类激酶抑制剂
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
ES2941897T3 (es) 2014-11-12 2023-05-26 Seagen Inc Compuestos que interaccionan con glicanos y procedimientos de uso
EP3231805B1 (en) * 2014-12-12 2020-03-04 Crystal Pharmatech Co. Ltd. Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
LT3305785T (lt) 2015-05-29 2021-11-10 Teijin Pharma Limited Pirido[3,4-d]pirimidino dariniai ir jų farmaciniu požiūriu priimtinos druskos
CN105037236B (zh) * 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108348514A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
JP2018526377A (ja) 2015-08-28 2018-09-13 ノバルティス アーゲー がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
ES2761885T3 (es) * 2015-08-28 2020-05-21 Novartis Ag Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
JP2018532750A (ja) 2015-11-02 2018-11-08 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
CN105541863B (zh) * 2016-02-16 2017-09-05 安纳康科学股份有限公司 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
WO2017162215A1 (zh) * 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
CN109071552B (zh) * 2016-04-22 2022-06-03 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
WO2017193872A1 (en) 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CN108290899B (zh) * 2016-06-06 2020-09-18 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
JP7106462B2 (ja) 2016-07-01 2022-07-26 ジー１ セラピューティクス， インコーポレイテッド Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3503923B1 (en) 2016-08-23 2023-10-04 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
ES2974991T3 (es) 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018073687A1 (en) 2016-10-20 2018-04-26 Pfizer Inc. Anti-proliferative agents for treating pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
JP2020502062A (ja) 2016-11-17 2020-01-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル アルキルピロロピリミジン類似体、及びその製造方法と使用方法
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018097297A1 (ja) 2016-11-28 2018-05-31 帝人ファーマ株式会社 ピリド［３，４－ｄ］ピリミジン誘導体及びその薬学的に許容される塩
ES2905437T3 (es) 2016-11-28 2022-04-08 Teijin Pharma Ltd Cristal de derivado de pirido[3,4-d]pirimidina o solvato del mismo
JP2019536805A (ja) 2016-12-05 2019-12-19 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法計画中の免疫応答の保護
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
EP3573619A4 (en) * 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
IL269357B2 (en) 2017-03-16 2024-10-01 Eisai R&D Man Co Ltd A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
FI3618875T3 (fi) 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
CN107118215B (zh) * 2017-05-06 2019-04-05 上海耀大生物科技有限公司 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN106946880B (zh) * 2017-05-06 2019-04-26 南京焕然生物科技有限公司 一种制备瑞博西尼中间体的方法
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CN108929324A (zh) * 2017-05-22 2018-12-04 南开大学 新型1,1-环丙基二酰胺衍生物的制备与应用
TW201906818A (zh) * 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
CA3067873A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of g1t38 and methods of manufacture thereof
WO2019026006A1 (en) 2017-08-03 2019-02-07 Novartis Ag THERAPEUTIC ASSOCIATION OF THIRD GENERATION EGFR TYROSINE KINASE INHIBITOR AND CYCLIN D KINASE INHIBITOR
MX2020002123A (es) 2017-08-25 2020-09-18 Sicor Soc It Corticosteroidi S R L Sales de ribociclib y formas en estado sólido de las mismas.
EP3676404B1 (en) 2017-08-31 2025-09-03 Novartis AG Methods of selecting a treatment for breast cancer patients
US11286259B2 (en) 2017-09-29 2022-03-29 Hangzhou Solipharma Co., Ltd. Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
WO2019082143A1 (en) 2017-10-27 2019-05-02 Fresenius Kabi Oncology Ltd. IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
EP3728228A1 (en) * 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2019123364A1 (en) 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
WO2019133864A1 (en) * 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3088381A1 (en) * 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
MA51846A (fr) 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US10723739B2 (en) 2018-05-14 2020-07-28 Apotex Inc. Processes for the preparation of Ribociclib and intermediates thereof
WO2019222521A1 (en) * 2018-05-16 2019-11-21 G1 Therapeutics, Inc. Cdk inhibitors for the treatment of neoplastic disorders
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
MA52806A (fr) 2018-06-05 2021-04-14 Crinetics Pharmaceuticals Inc Antagonistes du récepteur de la mélanocortine de sous-type 2 (mc2r) et leurs utilisations
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3107750A1 (en) 2018-07-27 2020-01-30 California Institute Of Technology Cdk inhibitors and uses thereof
AU2019321289B2 (en) 2018-08-13 2025-01-23 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
AU2019338032A1 (en) * 2018-09-13 2021-05-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140052A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide
TWI831916B (zh) 2019-02-12 2024-02-11 瑞士商諾華公司 包含tno155和瑞博西尼之藥物組合
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
TWI875756B (zh) 2019-05-05 2025-03-11 美商基尼特奇公司 Ｃｄｋ抑制劑
WO2020225827A1 (en) 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
IL288508B1 (en) * 2019-06-04 2025-10-01 Step Pharma S A S History of N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-H2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CR20220342A (es) 2019-12-16 2023-01-23 Lunella Biotech Inc Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
KR20220113985A (ko) * 2019-12-16 2022-08-17 루넬라 바이오테크 인코포레이티드 선택적 cdk 4/6 억제제 암 치료제
JP7672406B2 (ja) 2019-12-18 2025-05-07 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
CN116234803A (zh) 2019-12-23 2023-06-06 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
US12466829B2 (en) 2019-12-23 2025-11-11 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
EP4126244A4 (en) * 2020-03-27 2024-03-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF ANTI-HER2 ANTIBODIES AND CDK INHIBITORS FOR TUMOR TREATMENT
US20230219961A1 (en) * 2020-05-12 2023-07-13 Suzhou Alphama Biotechnology Co., Ltd. Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof
JP2023525100A (ja) 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
JP7406008B2 (ja) * 2020-05-12 2023-12-26 蘇州阿尓脈生物科技有限公司 Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
CN120865218A (zh) 2020-05-19 2025-10-31 法码科思莫斯有限公司 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物
CA3185467A1 (en) * 2020-06-11 2021-12-16 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
PE20240225A1 (es) 2020-11-24 2024-02-16 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CA3206906A1 (en) 2021-02-02 2022-08-11 Andras Herner Selective bcl-xl protac compounds and methods of use
EP4308553A4 (en) 2021-03-19 2025-01-22 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
WO2022207788A2 (en) 2021-04-01 2022-10-06 Krka, D.D., Novo Mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20240238284A1 (en) 2021-05-05 2024-07-18 Novartis Ag Compounds and compositions for the treatment of mpnst
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3217661A1 (en) 2021-07-16 2023-01-19 Alyssa VERANO Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
KR20240041340A (ko) * 2021-07-27 2024-03-29 보로노이 주식회사 피롤로피리미딘 유도체 화합물 및 이의 용도
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
CA3247849A1 (en) * 2022-04-08 2023-10-12 Baerenkraft Therapeutics, Llc Cdk9 inhibitors
CN119137102A (zh) 2022-04-08 2024-12-13 拜奥列司治疗有限公司 Cdk9抑制剂
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
AU2023273734A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2023336057A1 (en) 2022-08-31 2025-03-27 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
EP4605088A1 (en) * 2022-10-21 2025-08-27 Novartis AG Molecular glue degrader compounds and uses thereof
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
CN120752058A (zh) 2023-03-10 2025-10-03 诺华股份有限公司 panRAS抑制剂抗体-药物缀合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024231275A1 (en) 2023-05-05 2024-11-14 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025080628A1 (en) * 2023-10-10 2025-04-17 Biolexis Therapeutics, Inc. Bifunctional protac and molecular glue compounds and methods of use thereof
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib
WO2025235331A1 (en) * 2024-05-07 2025-11-13 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
CN120441576B (zh) * 2025-07-08 2025-09-26 山东大学 一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
CN120483984B (zh) * 2025-07-09 2025-10-10 山东大学 一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
BR122016021801B8 (pt) * 2002-01-22 2021-05-25 Warner Lambert Co compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
ATE410429T1 (de) 2002-03-07 2008-10-15 Hoffmann La Roche Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
CA2497440C (en) 2002-09-04 2011-03-22 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ATE433967T1 (de) * 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
AP2006003559A0 (en) 2003-09-05 2006-04-30 Neurogen Corp Ventis Pharmaceuticals Inc Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005085253A1 (en) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine derivatives
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
KR20080107466A (ko) 2006-03-09 2008-12-10 파마코페이아, 인코포레이티드 대사 장애 치료용 8-헤테로아릴퓨린 ｍｎｋ2 억제제
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
KR20100095020A (ko) * 2007-12-19 2010-08-27 암젠 인크 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물
NZ587271A (en) * 2008-02-06 2012-03-30 Novartis Ag Pyrrolo[2,3-d]pyrimidines containing a 7h-pyrrolo[2,3-d]pyrimidin-2-yl core and use thereof as tyrosine kinase inhibitors
CA2734802C (en) * 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CN102869358B (zh) 2010-04-13 2016-03-23 诺华股份有限公司 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合

Also Published As

Publication number Publication date
EP2716643A1 (en) 2014-04-09
PE20110419A1 (es) 2011-07-13
US8685980B2 (en) 2014-04-01
NZ591176A (en) 2012-11-30
AU2009284098B2 (en) 2012-03-29
CR20110101A (es) 2011-06-09
US20130184285A1 (en) 2013-07-18
CN102186856A (zh) 2011-09-14
EP2331547B1 (en) 2014-07-30
CA2734802E (en) 2010-02-25
ZA201100994B (en) 2011-12-28
LTC2331547I2 (lt) 2018-09-10
MY150560A (en) 2014-01-30
FR17C1059I1 (es) 2018-02-16
LTPA2017039I1 (lt) 2017-12-11
JP5560496B2 (ja) 2014-07-30
BRPI0917791A2 (pt) 2019-08-13
GEP20135785B (en) 2013-03-11
US8415355B2 (en) 2013-04-09
RS53574B1 (sr) 2015-02-27
US20100105653A1 (en) 2010-04-29
EA019094B1 (ru) 2014-01-30
US20140135312A1 (en) 2014-05-15
NO2017059I2 (no) 2017-11-13
CY2017042I1 (el) 2018-04-04
EA201100355A8 (ru) 2013-09-30
CN102186856B (zh) 2014-09-24
LUC00048I1 (es) 2017-11-15
US8962630B2 (en) 2015-02-24
MA32555B1 (fr) 2011-08-01
UA103628C2 (en) 2013-11-11
PL2331547T3 (pl) 2015-01-30
SMT201500017B (it) 2015-03-05
CU20110040A7 (es) 2011-12-28
NL300909I1 (es) 2017-11-10
TWI468409B (zh) 2015-01-11
US20210253578A1 (en) 2021-08-19
IL211164A0 (en) 2011-04-28
HN2011000542A (es) 2013-10-17
CY1115703T1 (el) 2017-01-25
IL211164A (en) 2016-09-29
CL2011000306A1 (es) 2011-06-24
TW201014858A (en) 2010-04-16
SI2331547T1 (sl) 2014-11-28
HRP20141018T1 (hr) 2015-02-13
FR17C1059I2 (fr) 2019-01-11
NL300909I2 (nl) 2017-12-19
US20180155351A1 (en) 2018-06-07
US9416136B2 (en) 2016-08-16
KR20110052713A (ko) 2011-05-18
DOP2011000057A (es) 2015-11-15
JP2012500785A (ja) 2012-01-12
CO6341561A2 (es) 2011-11-21
KR101353857B1 (ko) 2014-01-21
US20110152244A1 (en) 2011-06-23
HUS1700051I1 (hu) 2017-12-28
WO2010020675A1 (en) 2010-02-25
UY38935A (es) 2020-12-31
MX2011001879A (es) 2011-03-29
JP5882371B2 (ja) 2016-03-09
CY2017042I2 (el) 2018-04-04
EP2331547A1 (en) 2011-06-15
US20170183352A1 (en) 2017-06-29
CU24062B1 (es) 2014-12-26
ES2522346T3 (es) 2014-11-14
AR111763A2 (es) 2019-08-14
HK1156625A1 (en) 2012-06-15
KR20130140222A (ko) 2013-12-23
UY32067A (es) 2010-03-26
CN103788100A (zh) 2014-05-14
PT2331547E (pt) 2014-10-29
NO2017059I1 (no) 2017-11-13
LUC00048I2 (es) 2018-01-10
TN2011000062A1 (en) 2012-09-05
DK2331547T3 (da) 2014-11-03
CA2734802A1 (en) 2010-02-25
NI201100042A (es) 2011-08-09
BRPI0917791B1 (pt) 2022-03-22
AU2009284098A1 (en) 2010-02-25
EA201100355A1 (ru) 2011-10-31
JO2924B1 (en) 2015-09-15
CA2734802C (en) 2016-05-31
ECSP11010843A (es) 2011-05-31
ME01282B (me) 2013-06-20
JP2014129361A (ja) 2014-07-10
US20240043428A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
AR073116A1 (es) Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes.
AR110706A1 (es) Inhibidores de poli-adp ribosa polimerasa (parp)
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR066781A1 (es) Compuestos de imidazopirimidina inhibidores de cinasa
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
CO6410301A2 (es) 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR035716A1 (es) Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR087184A1 (es) Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR081649A1 (es) Compuestos heteroarilo nitrogenados
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
AR045510A1 (es) Derivados de 1,3 diazoles
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CO6140030A2 (es) Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3

Legal Events

Date Code Title Description
FC Refusal